Retatrutide is investigational and is not approved for public use. This page is for regulatory awareness, public-source documentation, and safety research only. It is not buying guidance and does not recommend, rank, verify, endorse, source, import, prescribe, sell, or facilitate access to any product.

Clinical trials

Retatrutide clinical trials

Published April 29, 2026Updated May 2, 2026ClinicalTrials.gov source check

Retatrutide is investigational. Public access is through clinical trial participation, not retail purchase or normal prescription.

Key takeaways

Where to check current studies

ClinicalTrials.gov is the primary public database for checking current retatrutide studies, study status, conditions, eligibility criteria, locations, and sponsor details. Trial records change, so check the live registry before relying on older summaries.

Source: ClinicalTrials.gov retatrutide search

What Lilly says is being studied

Lilly's retatrutide FAQ says Phase 3 clinical trials include obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

Source: Lilly retatrutide FAQ

Trial eligibility

This site does not determine eligibility or provide medical advice. A trial record may list inclusion criteria, exclusion criteria, contacts, and locations, but eligibility decisions belong to the study team and qualified healthcare professionals.

Sources

Public record review

Have a public record we should add?

Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.

Submit a public record